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The advent of new HCV treatments (Direct Acting Antivirals, DAAs) with >90% 
sustained viral response (SVR) rates in 8 to 12 weeks has ushered in an era of 
excitement about the possibility of elimination of HCV transmission.  Tantalizing 
theoretical mathematical models predicting dramatic reductions in HCV chronic 
prevalence and incidence with scale-up of HCV treatment for those at risk of 
transmission have fueled this optimism1. Recent reports of a substantial 
dramatic reduction in HCV incidence (~50% in 2 years) among HIV-infected 
MSM in the Netherlands after the roll-out of DAA therapy2 has provided the first 
piece of empirical evidence that HCV treatment as prevention may be more than 
just a theoretical idea.  
 
One major question is how the availability of DAAs translates in terms of 
numbers of individuals treated. In this issue, Zimmerman and authors describe 
the real-world treatment rates achieved in the DAA era in Germany, a setting 
where in theory all patients are eligible for treatment regardless of disease stage  
(Zimmerman et al. Real-world treatment for chronic hepatitis C infection in 
Germany. Analyses from drug prescription data, 2010 – 2015). The authors 
report an estimated 160,000 patients in Germany with diagnosed chronic HCV 
infection, and even more who are undiagnosed. Yet despite no restrictions on 
treatment in Germany, Zimmerman et al. estimated only 7,000 patients were 
treated within the statutory health insurance system  (covering 85% of the 
German population) during 2014, and just over 20,000 in 2015, below that 
which would have been expected based on the numbers of individual in need of 
therapy.  We are not surprised that universal access to treatment alone is not 
sufficient for achieving rapid and comprehensive provision of DAA therapy to 
those in need of it.  
 
First, improvements are needed in HCV diagnosis and assessment. As 
Zimmerman et al. note, no HCV screening policy exists in Germany, and studies 
have found 35-65% of those testing positive for HCV in general practices and 
emergency rooms were unaware of their status. Globally, many remain unaware 
of their HCV infection, including those at risk of transmission3. In settings where 
people who inject drugs (PWID) are a main risk group for transmission, targeted 
case-finding programs in addiction services, primary care, and prisons may be 
highly effective and cost-effective4,5. Nevertheless, in many developing country 
settings the costs of diagnosis and confirmation of HCV infection are still 
prohibitively high. Additionally a lack of data surrounding the epidemiology of 
HCV in many country settings developed and developing makes it difficult to 
develop efficient targeted case-finding strategies and to establish the cascade of 
care (from the burden of disease to diagnosed cases, treated and cured)5  
 
Second, universal access to therapy is likely required. Undoubtedly one of the 
most important issues facing HCV elimination is the high cost of DAA therapy, 
which continues to lead to prioritization of therapy in many settings. Indeed, 
Zimmerman et al. speculated that despite theoretical universal access to HCV 
treatment regardless of disease stage in Germany, physicians may have 
prioritized patients with advanced disease and put others on hold. Nevertheless, 
they note that ambiguities in the reimbursement system and fear of rejected 
claims may have led to a reluctance of clinicians to prescribe DAA therapy. In 
other settings prioritization and denial of insurance reimbursements may be a 
reality. European guidelines still prioritize HCV therapy for those with more 
advanced liver disease6. In the US, IDSA/AASLD guidelines no longer recommend 
treatment prioritization7, but insurers in many states continue to restrict 
therapy for those with less advanced disease8. This has important consequences 
for the HCV elimination agenda. Although prioritization of individuals with more 
severe liver disease may be an economic way of preventing end-stage liver 
disease and HCV-related mortality, it may work at odds to the prevention 
agenda. For example, PWID tend to be younger with less advanced liver disease 
and therefore strategies which target more severe liver disease may have little to 
no impact on the epidemic. Indeed, mathematical modeling in the UK showed 
that current prioritization of therapy to individuals with F3 or cirrhosis would 
have virtually no effect on HCV incidence among PWID9. However, analyses have 
shown that in many settings with low-moderate HCV prevalence among PWID it 
is more cost-effective to prioritize early therapy for individuals at risk of 
transmission due to substantial prevention benefits10. Still, concerns about costs 
of therapy and potential costs of retreatment of reinfections persist. Ongoing 
studies will shed light on the risk of reinfection in the DAA era, but studies in the 
IFN-era consistently show that the risk of reinfection among PWID after SVR is 
relatively low11,12. Nevertheless, as observed in the US, Medicaid restrictions 
based on drug use history8 (counter to IDSA/AASLD guidelines7) will hamper 
efforts to deliver HCV treatment to those at risk of transmission in order to 
prevent new infections.  
 
Third, once access is ensured, HCV treatment needs to be scaled-up, in particular 
to those at risk of transmission. Unfortunately, several barriers continue to 
thwart the scale-up of HCV treatment for these populations, particularly PWID. 
Studies have indicated that PWID are willing to undergo HCV therapy13, yet 
many who are diagnosed remain untreated. Provider concerns surrounding 
potential poor treatment outcomes among PWID persist, despite clinical trial 
evidence that DAA treatment outcomes among PWID are comparable to the 
broader population14,15. Additionally, established programs have been successful 
at treating HCV among PWID even in the IFN-based era; the most effective 
programs are built on existing infrastructure for drug user health such as 
addiction clinics, community health centers, and prisons. 
 
Fourth, HCV treatment needs to be combined with prevention scale-up to 
enhance impact, reduce reinfection, and ensure stable reductions in 
transmission occur. Harm reduction intervention such as opiate substitution 
therapy and needle and syringe programs are effective at reducing an 
individuals’ risk of HCV acquisition, particularly in combination16,17, and are 
crucial for enabling any treatment intervention to effectively treat current PWID.  
Combination HCV treatment and harm reduction strategies can potentially act 
synergistically to reduce HCV incidence18, as well as prevent reinfection post 
treatment. However, across the globe the coverage and quality of harm reduction 
service provision is often low19. In settings with differing modes of transmission 
other prevention interventions are likely required, such as efficient blood 
screening, effective sterilization of medical equipment, education of unofficial 
health care providers, and initiatives to prevent mother-to-child transmission 
and between men who have sex with men.  
 
Overall, the promise of HCV treatment as prevention is enormous, and universal 
access like in Germany is an important necessary, but as Zimmerman et al 
demonstrate not always sufficient, first step.  
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